Laevoroc Oncology Announces Publication Identifying Purine Nucleoside Phosphorylase (PNP) as Novel Metabolic Immune Checkpoint

Zug, Switzerland, 8 December 2022: Laevoroc Oncology (‘Laevoroc’ or ‘the company’), a privately-owned, Swiss oncology development company, announced today the publication of key preclinical data carried out at the University of California, Los Angeles (UCLA) which provides mechanistic insights into the immunoregulatory functions of purine nucleoside phosphorylase (PNP) with Laevoroc’s PNP inhibitor, LR 09.

Read full release.